Cargando…

Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease

The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer’s Disease (AD), permits to distinguish...

Descripción completa

Detalles Bibliográficos
Autores principales: Isella, Valeria, Crivellaro, Cinzia, Formenti, Anna, Musarra, Monica, Pacella, Sara, Morzenti, Sabrina, Ferri, Francesca, Mapelli, Cristina, Gallivanone, Francesca, Guerra, Luca, Appollonio, Ildebrando, Ferrarese, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293827/
https://www.ncbi.nlm.nih.gov/pubmed/35347453
http://dx.doi.org/10.1007/s00415-022-11086-y
_version_ 1784749721096552448
author Isella, Valeria
Crivellaro, Cinzia
Formenti, Anna
Musarra, Monica
Pacella, Sara
Morzenti, Sabrina
Ferri, Francesca
Mapelli, Cristina
Gallivanone, Francesca
Guerra, Luca
Appollonio, Ildebrando
Ferrarese, Carlo
author_facet Isella, Valeria
Crivellaro, Cinzia
Formenti, Anna
Musarra, Monica
Pacella, Sara
Morzenti, Sabrina
Ferri, Francesca
Mapelli, Cristina
Gallivanone, Francesca
Guerra, Luca
Appollonio, Ildebrando
Ferrarese, Carlo
author_sort Isella, Valeria
collection PubMed
description The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer’s Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level. We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n. 63) or negative (n. 64) amyloid marker (cerebrospinal fluid or amy-PET). Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare. Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases. The three rating approaches showed good total accuracy (77–78%), good to optimal sensitivity (81–93%), but poorer specificity (62–75%). VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases. Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology. Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-022-11086-y.
format Online
Article
Text
id pubmed-9293827
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-92938272022-07-20 Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease Isella, Valeria Crivellaro, Cinzia Formenti, Anna Musarra, Monica Pacella, Sara Morzenti, Sabrina Ferri, Francesca Mapelli, Cristina Gallivanone, Francesca Guerra, Luca Appollonio, Ildebrando Ferrarese, Carlo J Neurol Original Communication The aim of our study was to establish empirically to what extent reduced glucose uptake in the precuneus, posterior cingulate and/or temporo-parietal cortex (PCTP), which is thought to indicate brain amyloidosis in patients with dementia or MCI due to Alzheimer’s Disease (AD), permits to distinguish amyloid-positive from amyloid-negative patients with non-classical AD phenotypes at the single-case level. We enrolled 127 neurodegenerative patients with cognitive impairment and a positive (n. 63) or negative (n. 64) amyloid marker (cerebrospinal fluid or amy-PET). Three rating methods of FDG-PET scan were applied: purely qualitative visual interpretation of uptake images (VIUI), and visual reading assisted by a semi-automated and semi-quantitative tool: INLAB, provided by the Italian National Research Council, or Cortex ID Suite, marketed by GE Healthcare. Fourteen scans (11.0%) patients remained unclassified by VIUI or INLAB procedures, therefore, validity values were computed on the remaining 113 cases. The three rating approaches showed good total accuracy (77–78%), good to optimal sensitivity (81–93%), but poorer specificity (62–75%). VIUI showed the highest sensitivity and the lowest specificity, and also the highest proportion of unclassified cases. Cases with asymmetric temporo-parietal hypometabolism and a progressive aphasia or corticobasal clinical profile, in particular, tended to be rated as AD-like, even if biomarkers indicated non-amyloid pathology. Our findings provide formal support to the value of PCTP hypometabolism for single-level diagnosis of amyloid pathophysiology in atypical AD, but also highlight the risk of qualitative assessment to misclassify patients with non-AD PPA or CBS underpinned by asymmetric temporo-parietal hypometabolism. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00415-022-11086-y. Springer Berlin Heidelberg 2022-03-26 2022 /pmc/articles/PMC9293827/ /pubmed/35347453 http://dx.doi.org/10.1007/s00415-022-11086-y Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Communication
Isella, Valeria
Crivellaro, Cinzia
Formenti, Anna
Musarra, Monica
Pacella, Sara
Morzenti, Sabrina
Ferri, Francesca
Mapelli, Cristina
Gallivanone, Francesca
Guerra, Luca
Appollonio, Ildebrando
Ferrarese, Carlo
Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
title Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
title_full Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
title_fullStr Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
title_full_unstemmed Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
title_short Validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of Alzheimer’s Disease
title_sort validity of cingulate–precuneus–temporo-parietal hypometabolism for single-subject diagnosis of biomarker-proven atypical variants of alzheimer’s disease
topic Original Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293827/
https://www.ncbi.nlm.nih.gov/pubmed/35347453
http://dx.doi.org/10.1007/s00415-022-11086-y
work_keys_str_mv AT isellavaleria validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT crivellarocinzia validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT formentianna validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT musarramonica validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT pacellasara validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT morzentisabrina validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT ferrifrancesca validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT mapellicristina validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT gallivanonefrancesca validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT guerraluca validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT appollonioildebrando validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease
AT ferraresecarlo validityofcingulateprecuneustemporoparietalhypometabolismforsinglesubjectdiagnosisofbiomarkerprovenatypicalvariantsofalzheimersdisease